Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  2. BHC

(BHC)

0.00

0.00 (0.00%)

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
26.03.2026

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026 LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education.

Is the Options Market Predicting a Spike in Bausch Health Stock?
24.03.2026

Is the Options Market Predicting a Spike in Bausch Health Stock?

Investors need to pay close attention to BHC stock based on the movements in the options market lately.

Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?
20.03.2026

Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm
13.03.2026

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation , (“ BLCO " or the "Company") ( NYSE : BLCO ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
23.02.2026

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada.

Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
20.02.2026

Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?

IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.

Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats
19.02.2026

Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats

Bausch + Lomb delivered 7% constant currency Q4 revenue growth and 27% adjusted EBITDA growth, reinforcing strong operating leverage. I maintain my Buy rating on BLCO, citing robust revenue momentum, promising product pipelines, and a path toward improved profitability and valuation. BLCO targets 5–7% annual revenue growth through 2028, driven by innovation in contact lenses, dry eye therapies, and premium intraocular lenses.

Видео

13.11.2025
Positive
Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Пресс-релизы

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
26.03.2026

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026 LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education.

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm
13.03.2026

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation , (“ BLCO " or the "Company") ( NYSE : BLCO ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
23.02.2026

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada.

Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
19.02.2026

Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres

The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical use LAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied antibiotic for this use.